ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis

Christina Christoffersen; Emil D Bartels; Annemarie Aarup; Lars B Nielsen; Tanja X Pedersen

doi:10.1016/j.ejphar.2017.03.053

ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis

Eur J Pharmacol. 2017 Dec 5:816:154-160. doi: 10.1016/j.ejphar.2017.03.053. Epub 2017 Mar 25.

Authors

Christina Christoffersen¹, Emil D Bartels², Annemarie Aarup³, Lars B Nielsen⁴, Tanja X Pedersen⁵

Affiliations

¹ Department of Clinical Biochemistry, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Oe, Denmark; Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark. Electronic address: Christina.Christoffersen@regionh.dk.
² Department of Clinical Biochemistry, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Oe, Denmark. Electronic address: Emil.Daniel.Bartels@regionh.dk.
³ Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark. Electronic address: nkt125@alumni.ku.dk.
⁴ Department of Clinical Biochemistry, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Oe, Denmark; Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark; Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark. Electronic address: Lars.Bo.Nielsen@regionh.dk.
⁵ Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark. Electronic address: tanjax@sund.ku.dk.

PMID: 28351665
DOI: 10.1016/j.ejphar.2017.03.053

Abstract

Chronic kidney disease affects as much as 13% of the population, and is associated with a markedly increased risk of developing cardiovascular disease. One of the underlying reasons is accelerated development of atherosclerosis. This can be ascribed both to increased occurrence of traditional cardiovascular risk factors, and to risk factors that may be unique to patients with chronic kidney disease. The latter is reflected in the observation that the current treatment modalities, mainly directed against traditional risk factors, are insufficient to prevent cardiovascular disease in the patient with chronic kidney disease. This review discusses mechanisms accelerating uremic atherosclerosis with a specific focus on the putative roles of apolipoprotein(apo)s B and M that may be particularly important in patients with chronic kidney disease.

Keywords: ApoB; ApoM; Atherosclerosis; Lipoprotein(a); S1P; Uremia.

Publication types

Review

MeSH terms

Animals
Apolipoproteins B / metabolism*
Apolipoproteins M / metabolism*
Atherosclerosis / drug therapy
Atherosclerosis / etiology*
Atherosclerosis / metabolism*
Humans
Molecular Targeted Therapy
Uremia / complications*

Substances

Apolipoproteins B
Apolipoproteins M